Verve Therapeutics surged 74.8% after hours to $10.96 following takeover speculation, while Eli Lilly slipped 1.4% to $807.58 during regular trade.

Lilly will acquire Verve Therapeutics and a pipeline of one-time treatments for cardiovascular diseases in a deal worth up to US$1.3 billion.

Prior to the VERV deal, Lilly announced that it had entered into agreements to acquire Scorpion Therapeutics’ oncology drug and SiteOne Therapeutics’ non-opioid pain candidate.

Key Points Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could ...

As part of its long-term investment in women’s sports, Eli Lilly will be present at the WNBA All-Star Game through breast cancer awareness activations.

Key Points Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is ...

Eli Lilly and Company (NYSE: LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. An array of pharmaceutical pills with the company’s logo on the bottle.